Table of Contents Show
The global medical tourism industry has long been plagued by a fundamental problem: patients seeking affordable, quality healthcare abroad are forced to navigate a fragmented landscape of unverified clinics, opaque pricing structures, and unreliable intermediaries. Pune-based health technology startup CureMeAbroad is building the infrastructure to change that — and its latest funding milestone signals growing investor confidence in its vision.
CureMeAbroad has closed a $600,000 pre-seed funding round backed by five angel investors — Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna, and Vikrant Potnis. The capital infusion marks a significant early vote of confidence for a platform that was founded less than a year ago, in June 2025, by Aditya Oza and Mikhail Bohra.
A Platform Built for Trust and Transparency
At its core, CureMeAbroad functions as an AI-powered discovery and matching platform. It aggregates a directory of over 6,000 hospitals spread across 47 countries and 45 medical specialties, giving patients a structured, data driven way to evaluate their treatment options internationally. The platform also maintains partnerships with more than 380 accredited hospitals in leading medical tourism destinations, including Mexico, Turkey, Thailand, India, and Georgia.
What differentiates CureMeAbroad from conventional medical tourism agencies is its proprietary AI cost estimator — a tool trained across hundreds of medical procedures — that delivers transparent pricing to patients before they commit to any treatment plan. The platform is HIPAA certified, underscoring its commitment to rigorous data privacy standards in handling sensitive patient information.
Also Read: Unbound Secures ₹8 Crore in Funding from Fireside Ventures to Enter Men’s Personal Care Market
Strategic Deployment of Capital
The pre-seed funds will be channelled into three key areas: upgrading the AI cost estimator, enhancing the platform’s clinical matching capabilities, and constructing a multilingual patient data layer that underpins its search and discovery engine. Each of these investments directly addresses a gap that has historically undermined trust in medical tourism — from inconsistent cost information to language barriers that complicate cross border healthcare decisions.
Eyes on Emerging Markets
Looking ahead, CureMeAbroad has identified the GCC, United Kingdom, and African markets as its primary expansion targets. These regions represent a significant untapped demand for accessible, trustworthy international healthcare navigation.
In an industry where patient vulnerability is high and reliable information is scarce, CureMeAbroad’s data first, AI-driven approach positions it as a meaningful contender in the evolving global health technology landscape. The road ahead is ambitious — but the foundation, it appears, is being built with intention.
